Rafferty Asset Management’s KalVista Pharmaceuticals KALV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $530K | Buy |
46,901
+20,632
| +79% | +$233K | ﹤0.01% | 875 |
|
|
2025
Q1 | $303K | Sell |
26,269
-28,197
| -52% | -$325K | ﹤0.01% | 964 |
|
|
2024
Q4 | $461K | Buy |
54,466
+10,636
| +24% | +$90.1K | ﹤0.01% | 927 |
|
|
2024
Q3 | $508K | Buy |
+43,830
| New | +$508K | ﹤0.01% | 926 |
|
|
2022
Q2 | – | Sell |
-47,549
| Closed | -$701K | – | 1179 |
|
|
2022
Q1 | $701K | Sell |
47,549
-16,637
| -26% | -$245K | ﹤0.01% | 860 |
|
|
2021
Q4 | $849K | Buy |
64,186
+25,586
| +66% | +$338K | ﹤0.01% | 943 |
|
|
2021
Q3 | $674K | Sell |
38,600
-21,124
| -35% | -$369K | ﹤0.01% | 976 |
|
|
2021
Q2 | $1.43M | Buy |
59,724
+41,425
| +226% | +$993K | 0.01% | 777 |
|
|
2021
Q1 | $470K | Buy |
+18,299
| New | +$470K | ﹤0.01% | 981 |
|